Reuters logo
BRIEF-Adamas presents positive phase 1A data
May 22, 2017 / 12:45 PM / 7 months ago

BRIEF-Adamas presents positive phase 1A data

May 22 (Reuters) - Adamas Pharmaceuticals Inc:

* Adamas presents positive phase 1A data of ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy

* Adamas Pharmaceuticals - phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of vimpat

* Says multi-dose phase 1b steady state study ongoing, with topline data expected in Q3 2017

* Adamas Pharmaceuticals - data from study showed all four formulations of ADS-4101 to be safe and well tolerated when compared to vimpat-treated group Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below